<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Christos S. Karapetis(Clínica Alemana), John Zalcberg(Monash Health), Shirin Khambata‐Ford(Daiichi Sankyo (United States)), Chris J. O’Callaghan(Unknown), Sonia Robitaille(Ontario Institute for Cancer Research), Haji Chalchal, Timothy Price(Basil Hetzel Institute), Dongsheng Tu(Ontario Institute for Cancer Research), Derek J. Jonker(University of Ottawa), R. J. Simes(The University of Sydney), Niall C. Tebbutt(Austin Health), Christiane Langer(Bristol-Myers Squibb (United States)), Jeremy Shapiro(Cabrini Hospital), Malcolm J. Moore(University Health Network), Heather‐Jane Au, Lois E. Shepherd(Ontario Institute for Cancer Research)
Cited by 3,595
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k